Pharos Pharmaceuticals
- Company typePrivate
- Founded2009
- HeadquartersLudhiana, India
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Pharos Pharmaceuticals firmographics
Firmographics- Name
- Pharos Pharmaceuticals
- Legal name
- Pharos Healthcare Pvt. Ltd.
- Website
- https://pharospharmaceuticals.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Pharos Pharmaceuticals industry classification
Industry- Product category
- Generic Pharmaceutical Manufacturing & Distribution
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)
Keywords
Where Pharos Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Ludhiana
- HQ country
- India
- HQ region
- Asia
Offices3 records
Markets served
Pharos Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
Revenue model
- Pharmaceutical Product Sales: Pharos Pharmaceuticals generates revenue by outsourcing and distributing pharmaceutical products including Tablets, Syrups, Gels, Capsules, and Psychiatric Products. Products are manufactured by WHO/GMP certified companies and distributed to healthcare providers across India.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Pharos Pharmaceuticals product offering
Product offeringCore offering
Pharos Pharmaceuticals outsources and distributes a broad portfolio of pharmaceutical formulations — including tablets, syrups, gels, capsules, injectables, and soft gel capsules — from WHO/GMP certified manufacturers for sale to healthcare providers. Its products span multiple therapy areas: Surgery, Ortho, Gynae, General Physician, Chest, ENT, and Dental, with branded formulations such as Antigram 625, Degram, Dicper, Dicper-Gel, Cefta, Ceme-LB, Phakast Tab, Phalax Syrup/Tab, Doxti-OD, Phadfer, Phacal-D3, Phaspa-Tab, Phanac, Phazol-D, CEOF Tab, Phatuss-P, Phatuss-EX, Solase, and Phamin Cap/Inject.
Product overview
Pharos Pharmaceuticals is a pharmaceutical company established in 2009 that outsources pharmaceutical products from WHO/GMP certified companies. The company offers a broad portfolio of tablets, syrups, gels, and capsules across multiple therapeutic categories including Surgery, Ortho (Dicper-Gel), Gynae (Doxti-OD, Phadfer Tab/Syrup), General Physician (Phakast Tab, Phalax Syrup/Tab, Phacal D3, Phaspa Tab, Phatuss-P, Phatuss-EX, Solase, Phamin Cap/Inject), Chest (CEOF Tab), and psychiatric products. The product line includes branded formulations such as Antigram 625, Degram, Dicper, Cefta, Ceme-LB, CEOF-Tab, Phanac, and Phazol-D. Manufacturing is conducted under strict WHO/GMP guidelines with quality standards equivalent to USFDA and UKMHRA requirements.
Differentiator
Problem solved
Functional benefit
Products and services
- Antigram 625
Companies that use Pharos Pharmaceuticals
Customer profileNamed customers3 records
Segments7 records
Ideal customer profiles1 record
Pharos Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Pharos Pharmaceuticals partnerships and signals
Strategic signalScale indicators3 records
Recent moves3 records
Expansion highlights3 records
Pharos Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Mankind Pharma: Leading Indian pharmaceutical company with a broad multi-therapy-area portfolio marketed to general physicians and specialists through an extensive field force. Highly comparable business model to Pharos in terms of targeting Indian healthcare providers with branded generic formulations across diverse specialties.
- Ajanta Pharma: Indian specialty pharmaceutical company with branded generic formulations across multiple therapeutic areas including cardiology, dermatology, and ophthalmology. Comparable to Pharos in serving Indian healthcare providers with branded generic products, though Ajanta has stronger export franchise.
- Marksans Pharma: India-based pharmaceutical company with branded and generic formulations across multiple therapy areas. Comparable in model to Pharos as an India-based pharma marketing company, with similar focus on multi-therapy-area generic distribution.
- Eris Lifesciences: India-focused branded generic pharmaceutical company that builds chronic-care portfolios through acquisitions and in-licensing. Comparable to Pharos in targeting Indian prescribers with branded formulations sourced from third-party manufacturers, though Eris is concentrated in chronic rather than acute care.
- JB Chemicals & Pharmaceuticals: Indian pharmaceutical company with a branded formulation portfolio across multiple therapy areas including cardiology, gastroenterology, and gynecology. Comparable to Pharos in marketing branded generics to Indian physicians across diverse specialties, though JBCPL owns its own manufacturing.
- Unichem Laboratories: Mid-sized Indian pharmaceutical company with branded formulations across multiple therapy areas including cardiology, neurology, and gastroenterology. Comparable in business model to Pharos as an India-focused branded generic pharma, though with larger scale and own manufacturing.
Broad incumbents
- Cipla: One of India's largest pharmaceutical companies with a broad portfolio of branded generics across respiratory, cardiology, urology, and other therapy areas. Comparable in therapy-area breadth to Pharos, though Cipla operates at vastly larger scale with global manufacturing footprint.
- Torrent Pharmaceuticals: Major Indian pharmaceutical company with a strong branded generic portfolio in cardiovascular, central nervous system, and gastroenterology therapy areas. Comparable to Pharos in targeting Indian specialists with branded generics, though at substantially larger scale.
- Alkem Laboratories: Among the top 10 Indian pharmaceutical companies with a diversified branded generic portfolio across multiple therapeutic areas. Comparable to Pharos in targeting Indian prescribers across therapy areas, though Alkem operates at much larger scale with its own manufacturing infrastructure.
- Micro Labs: Privately held Indian pharmaceutical company with a broad branded generic portfolio spanning multiple therapeutic areas. Comparable to Pharos in its privately-held Indian pharma marketing model, though Micro Labs is significantly larger with its own manufacturing.
Market position
Strengths1 record
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Pharos Pharmaceuticals social profiles
Digital presencePharos Pharmaceuticals compliance and trust
Trust signalCompliance3 records
Pharos Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pharos Pharmaceuticals leadership team
Management profileNumber of profiles
Pharos Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pharos Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pharos Pharmaceuticals
What does Pharos Pharmaceuticals do?
Pharos Pharmaceuticals outsources and distributes a broad portfolio of pharmaceutical formulations — including tablets, syrups, gels, capsules, injectables, and soft gel capsules — from WHO/GMP certified manufacturers for sale to healthcare providers. Its products span multiple therapy areas: Surgery, Ortho, Gynae, General Physician, Chest, ENT, and Dental, with branded formulations such as Antigram 625, Degram, Dicper, Dicper-Gel, Cefta, Ceme-LB, Phakast Tab, Phalax Syrup/Tab, Doxti-OD, Phadfer, Phacal-D3, Phaspa-Tab, Phanac, Phazol-D, CEOF Tab, Phatuss-P, Phatuss-EX, Solase, and Phamin Cap/Inject.
Is Pharos Pharmaceuticals a public or private company?
Pharos Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.
When was Pharos Pharmaceuticals founded?
Pharos Pharmaceuticals was founded in 2009. It employs 11 to 50 people.
Where is Pharos Pharmaceuticals based?
Pharos Pharmaceuticals is headquartered in Ludhiana, India, in the Asia region.
How does Pharos Pharmaceuticals make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Pharos Pharmaceuticals's main competitors?
Direct peers on record are Mankind Pharma, Ajanta Pharma, Marksans Pharma, Eris Lifesciences, JB Chemicals & Pharmaceuticals and Unichem Laboratories. Broad incumbents are Cipla, Torrent Pharmaceuticals, Alkem Laboratories and Micro Labs.
Does Pharos Pharmaceuticals have an API?
No public API is recorded for Pharos Pharmaceuticals.
What industry is Pharos Pharmaceuticals in?
Pharos Pharmaceuticals's product category is Generic Pharmaceutical Manufacturing & Distribution. Its primary akta.pro industry code is HLAIABAJ, Generic ANDA/Regulatory Affairs & Submissions. Its NAICS code is 325412 and its SIC code is 2834.